Pfizer settles Celebrex antitrust class action for $94 million

A class of direct purchasers who allege that Pfizer used fraudulent patents to delay generic competition for its anti-inflammatory drug Celebrex have reached a $94 million settlement agreement with Pfizer.

In August, 2017, U.S. District Judge Arenda L. Wright Allen certified a class of 32 direct purchasers who claim Pfizer cost Celebrex buyers hundreds of millions of dollars by abusing the courts and the U.S. Patent and Trademark Office to extend its exclusive window to sell the drug.

The case is In re Celebrex (Celecoxib) Antitrust Litigation, case number 2:14-cv-00361, in the U.S. District Court for the Eastern District of Virginia.

Steve Larson
An experienced trial lawyer who handles both hourly and contingent fee cases, Steve has expertise in class actions, antitrust litigation, securities litigation, corporate disputes, intellectual property disputes, unfair competition claims, and disputes involving family wealth. Steve regularly represents individuals and businesses in federal and state court and has obtained class-wide recovery in multiple class actions. A veteran practitioner, Steve's clients value his creative approach to resolving complex litigation matters.


Share on facebook
Share on twitter
Share on google
Share on linkedin

Legal Disclaimer

The information contained in this blog does not constitute legal advice, and does not create an attorney-client relationship. We make no claims, promises or guarantees about the accuracy, completeness, or adequacy of the information contained in or linked to this blog.